Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

20 sept. 2017 02h01 HE | Source: Shire Pharmaceuticals Group

Shire and Shionogi Announce Positive Topline Results for INTUNIV® Evaluated in Phase 3 Clinical Trial in Adults with ADHD

Shire and Shionogi Announce Positive Topline Results for INTUNIV® (guanfacine hydrochloride prolonged release) Evaluated in Phase 3 Clinical Trial in Adults with ADHD Topline results revealed...
15 sept. 2017 07h00 HE | Source: Shire Pharmaceuticals Group

Shire Debuts MYDAYIS® and New Research at the 30th Annual Psych Congress

Shire Debuts MYDAYIS® and New Research at the 30th Annual Psych Congress Lexington, MA - September 15, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) will share new Attention Deficit Hyperactivity...
12 sept. 2017 07h01 HE | Source: Shire Pharmaceuticals Group

Shire Receives FDA Fast Track Designation for SHP607 for the Prevention of Chronic Lung Disease in Extremely Premature Infants

Shire Receives FDA Fast Track Designation for SHP607 for the Prevention of Chronic Lung Disease in Extremely Premature Infants Cambridge, Mass. - September 12, 2017 - Shire plc (LSE: SHP, NASDAQ:...
11 sept. 2017 07h02 HE | Source: Shire Pharmaceuticals Group

Shire plc : Elections for the interim dividend in respect of the six months to June 30, 2017

Elections for the interim dividend in respect of the six months to June 30, 2017 September 11, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announced on August 3, 2017, an interim...
11 sept. 2017 07h01 HE | Source: Shire Pharmaceuticals Group

Shire's Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces HAE Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial

Shire's Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces Hereditary Angioedema Monthly Attack Rate Versus Placebo in a Phase 3...
07 sept. 2017 07h01 HE | Source: Shire Pharmaceuticals Group

Shire to participate at two upcoming investor conferences

Shire to participate at two upcoming investor conferences Lexington, MA, USA - September 7, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Flemming Ornskov, MD, Chief Executive Officer,...
01 sept. 2017 06h31 HE | Source: Shire Pharmaceuticals Group

Shire plc : Total voting rights

Total Voting Rights September 1, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company"), in accordance with 5.6.1R of the Financial Conduct Authority's (the "FCA") Disclosure...
29 août 2017 10h31 HE | Source: Shire Pharmaceuticals Group

Shire plc : Director/PDMR Shareholding

Director/PDMR Shareholding August 29, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) Notification of transaction by person discharging managerial responsibilities 1. Details of the person discharging...
28 août 2017 07h00 HE | Source: Shire Pharmaceuticals Group

Shire plc : MYDAYIS(TM) (mixed salts of a single-entity amphetamine product), Shire's New Once-Daily ADHD Treatment, Now Available in the U.S.

For U.S. Audiences Only MYDAYIS(TM) (mixed salts of a single-entity amphetamine product), Shire's New Once-Daily ADHD Treatment, Now Available in the U.S. Mydayis, which is now...
25 août 2017 07h00 HE | Source: Shire Pharmaceuticals Group

Shire plc : Shire Announces Collaboration with MicroHealth to Address Unique Needs of Hemophilia A and B Patients with Inhibitors

Shire Announces Collaboration with MicroHealth to Address Unique Needs of Hemophilia A and B Patients with Inhibitors Collaboration leverages digital technology to provide free and secure care...

Page précédente